New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

Share :
Published: 12 Jun 2015
Views: 2144
Rating:
Save
Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.

Read the news story for more.